Trial Profile
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Tumour necrosis factor alpha inhibitors
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CATARA
- 11 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Sep 2010 New trial record